Executive control in Parkinson's disease: Effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance

Jos J.  Adam; Hanna van Houdt; B. Scholtissen; Veerle Visser-Vandewalle; Ania Winogrodzka; A. Duits

doi:10.1016/j.neulet.2011.06.016

Executive control in Parkinson's disease: Effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance

Jos J. Adam^*, Hanna van Houdt, B. Scholtissen, Veerle Visser-Vandewalle, Ania Winogrodzka, A. Duits

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Using an anti-cue keypress task, we examined executive control in Parkinson's disease (PD) patients treated with deep brain stimulation (DBS) of the subthalamic nucleus (STN) and dopaminergic medication. Across sessions, we varied stimulation (on, off) and dopaminergic medication (on, off). Reaction time (RT) results of the PD patients and their age-matched controls showed a consistent pattern of RT costs and benefits generated by anti-cues with short and long preparation intervals, respectively. This pattern was evident in all sessions, except when DBS stimulation and medication were off. In this condition PD patients showed no RT benefits. These findings are discussed in terms of an executive control process that suppresses the automatic but inappropriate response activation generated by anti-cues. In PD this mechanism is severely compromised but it can be remediated by dopaminergic medication and DBS, suggesting an essential role of the basal ganglia in the selection and suppression of competing responses.

Original language	English
Pages (from-to)	113-117
Number of pages	5
Journal	Neuroscience Letters
Volume	500
Issue number	2
Early online date	17 Jun 2011
DOIs	https://doi.org/10.1016/j.neulet.2011.06.016
Publication status	Published - 15 Aug 2011
Externally published	Yes

Fingerprint

Keywords

Aged
Benserazide/therapeutic use
Benzothiazoles/therapeutic use
Carbidopa/therapeutic use
Cues
*Deep Brain Stimulation
Dopamine Agents/*therapeutic use
Drug Combinations
Female
Humans
Levodopa/therapeutic use
Male
Middle Aged
Parkinson Disease/physiopathology/*psychology/therapy
Pergolide/therapeutic use
*Psychomotor Performance
Reaction Time
Subthalamic Nucleus/physiopathology
Anti-cue
Response selection
Executive control

Cite this

Adam, J. J., van Houdt, H., Scholtissen, B., Visser-Vandewalle, V., Winogrodzka, A., & Duits, A. (2011). Executive control in Parkinson's disease: Effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance. Neuroscience Letters, 500(2), 113-117. https://doi.org/10.1016/j.neulet.2011.06.016

@article{56a00bbc0fd248108e5e523162d69f4f,

title = "Executive control in Parkinson's disease: Effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance",

abstract = "Using an anti-cue keypress task, we examined executive control in Parkinson's disease (PD) patients treated with deep brain stimulation (DBS) of the subthalamic nucleus (STN) and dopaminergic medication. Across sessions, we varied stimulation (on, off) and dopaminergic medication (on, off). Reaction time (RT) results of the PD patients and their age-matched controls showed a consistent pattern of RT costs and benefits generated by anti-cues with short and long preparation intervals, respectively. This pattern was evident in all sessions, except when DBS stimulation and medication were off. In this condition PD patients showed no RT benefits. These findings are discussed in terms of an executive control process that suppresses the automatic but inappropriate response activation generated by anti-cues. In PD this mechanism is severely compromised but it can be remediated by dopaminergic medication and DBS, suggesting an essential role of the basal ganglia in the selection and suppression of competing responses.",

keywords = "Aged, Benserazide/therapeutic use, Benzothiazoles/therapeutic use, Carbidopa/therapeutic use, Cues, *Deep Brain Stimulation, Dopamine Agents/*therapeutic use, Drug Combinations, Female, Humans, Levodopa/therapeutic use, Male, Middle Aged, Parkinson Disease/physiopathology/*psychology/therapy, Pergolide/therapeutic use, *Psychomotor Performance, Reaction Time, Subthalamic Nucleus/physiopathology, Anti-cue, Response selection, Executive control",

author = "Adam, {Jos J.} and {van Houdt}, Hanna and B. Scholtissen and Veerle Visser-Vandewalle and Ania Winogrodzka and A. Duits",

note = "PMID:21704125",

year = "2011",

month = aug

day = "15",

doi = "10.1016/j.neulet.2011.06.016",

language = "English",

volume = "500",

pages = "113--117",

journal = "Neuroscience Letters",

issn = "0304-3940",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

Executive control in Parkinson's disease : Effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance. / Adam, Jos J. ; van Houdt, Hanna; Scholtissen, B.; Visser-Vandewalle, Veerle; Winogrodzka, Ania; Duits, A.

In: Neuroscience Letters, Vol. 500, No. 2, 15.08.2011, p. 113-117.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Executive control in Parkinson's disease

T2 - Effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance

AU - Adam, Jos J.

AU - van Houdt, Hanna

AU - Scholtissen, B.

AU - Visser-Vandewalle, Veerle

AU - Winogrodzka, Ania

AU - Duits, A.

N1 - PMID:21704125

PY - 2011/8/15

Y1 - 2011/8/15

N2 - Using an anti-cue keypress task, we examined executive control in Parkinson's disease (PD) patients treated with deep brain stimulation (DBS) of the subthalamic nucleus (STN) and dopaminergic medication. Across sessions, we varied stimulation (on, off) and dopaminergic medication (on, off). Reaction time (RT) results of the PD patients and their age-matched controls showed a consistent pattern of RT costs and benefits generated by anti-cues with short and long preparation intervals, respectively. This pattern was evident in all sessions, except when DBS stimulation and medication were off. In this condition PD patients showed no RT benefits. These findings are discussed in terms of an executive control process that suppresses the automatic but inappropriate response activation generated by anti-cues. In PD this mechanism is severely compromised but it can be remediated by dopaminergic medication and DBS, suggesting an essential role of the basal ganglia in the selection and suppression of competing responses.

AB - Using an anti-cue keypress task, we examined executive control in Parkinson's disease (PD) patients treated with deep brain stimulation (DBS) of the subthalamic nucleus (STN) and dopaminergic medication. Across sessions, we varied stimulation (on, off) and dopaminergic medication (on, off). Reaction time (RT) results of the PD patients and their age-matched controls showed a consistent pattern of RT costs and benefits generated by anti-cues with short and long preparation intervals, respectively. This pattern was evident in all sessions, except when DBS stimulation and medication were off. In this condition PD patients showed no RT benefits. These findings are discussed in terms of an executive control process that suppresses the automatic but inappropriate response activation generated by anti-cues. In PD this mechanism is severely compromised but it can be remediated by dopaminergic medication and DBS, suggesting an essential role of the basal ganglia in the selection and suppression of competing responses.

KW - Aged

KW - Benserazide/therapeutic use

KW - Benzothiazoles/therapeutic use

KW - Carbidopa/therapeutic use

KW - Cues

KW - Deep Brain Stimulation

KW - Dopamine Agents/therapeutic use

KW - Drug Combinations

KW - Female

KW - Humans

KW - Levodopa/therapeutic use

KW - Male

KW - Middle Aged

KW - Parkinson Disease/physiopathology/psychology/therapy

KW - Pergolide/therapeutic use

KW - Psychomotor Performance

KW - Reaction Time

KW - Subthalamic Nucleus/physiopathology

KW - Anti-cue

KW - Response selection

KW - Executive control

U2 - 10.1016/j.neulet.2011.06.016

DO - 10.1016/j.neulet.2011.06.016

M3 - Article

VL - 500

SP - 113

EP - 117

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 2

ER -

Access to Document

10.1016/j.neulet.2011.06.016